Compare stocks

Aiforia Technologies Oyj, established in 2013 and headquartered in Helsinki, Finland, develops deep learning artificial intelligence (AI) software for pathology image analysis. The company's core products include AI-supported diagnostic suites for breast, lung, and prostate cancers, as well as Aiforia Create, a platform enabling users to develop and validate proprietary AI models for 2D image analysis. Aiforia serves a global clientele, including pharmaceutical and biotechnology companies, contract research organizations, clinical laboratories, and academic institutions. The company operates internationally, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and representatives across Europe and North America. Aiforia's strategic focus includes expanding its clinical and preclinical offerings, forming strategic partnerships, and achieving positive cash flow from operating activities. (,)

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.